<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02206178</url>
  </required_header>
  <id_info>
    <org_study_id>CHU-0202</org_study_id>
    <secondary_id>2013-000668-27</secondary_id>
    <nct_id>NCT02206178</nct_id>
  </id_info>
  <brief_title>Acetaminophen's Antinociceptive Effect When Associated With N-Acetylcysteneine</brief_title>
  <acronym>PANACE</acronym>
  <official_title>ACETAMINOPHEN ANTINOCICEPTIVE EFFECT WHEN ASSOCIATED WITH N-ACETYLCYSTENEINE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <brief_summary>
    <textblock>
      Acetaminophen is one of the most widely used analgesic in the world, recommended for the&#xD;
      symptomatic treatment of fever and pain.&#xD;
&#xD;
      The purpose of this study is to assess the effectiveness of acetaminophen in association with&#xD;
      N-acetylcysteine.&#xD;
&#xD;
      The objective of this study is to evaluate if the association in healthy volunteers of&#xD;
      acetaminophen and N-acétylcystéine&#xD;
&#xD;
        1. - decrease the antinociceptive effect of acetaminophen in comparison to a group control&#xD;
&#xD;
        2. - and if this antinociceptive effect may depend of the genetic polymorphism of GSH&#xD;
           enzyme.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Period 1 : To Day -4 to Day 0&#xD;
&#xD;
      Day -4 at 8:00 am at Clinical Pharmacology Center&#xD;
&#xD;
        -  Inclusion Visit, signature of Informed consent form, clinical exam.&#xD;
&#xD;
        -  Training test&#xD;
&#xD;
        -  Blood sample (GSH, pharmacogenetic, Biochemistry assay)&#xD;
&#xD;
        -  Randomization and attribution of treatment for the fisrt study period at home: (day -4,&#xD;
           -3, -2, -1) 4 days of oral acetaminophen and [N-acetylcysteine or placebo] according to&#xD;
           the randomization plan.&#xD;
&#xD;
      At day -3, -2 and -1 a salivary sample will be done to control the treatment compliance.&#xD;
&#xD;
      Day 0 at Clinical Pharmacology Center Clinical examination Measurement of the basal pain&#xD;
      thresholds and pain evaluation (Visual Analog Scales) Blood and urinary sample (acetaminophen&#xD;
      and GSH assay)&#xD;
&#xD;
      T0 : Administration of product: acetaminophen and [N-acetylcysteine or placebo]&#xD;
&#xD;
      T0+1H: Thermal stimulation according to the established paradigm (threshold temperature +3°C&#xD;
      ) and pain evaluation (Visual Analog Scales)&#xD;
&#xD;
      T0+2H: Thermal stimulation according to the established paradigm (threshold temperature +3°C&#xD;
      ) and pain evaluation (Visual Analog Scales) and Blood sample (acetaminophen assay)&#xD;
&#xD;
      T0+3H: Thermal stimulation according to the established paradigm (threshold temperature +3°C&#xD;
      ) and pain evaluation (Visual Analog Scales)&#xD;
&#xD;
      T0+4H: Thermal stimulation according to the established paradigm (threshold temperature +3°C&#xD;
      ) and pain evaluation (Visual Analog Scales) and Blood and urinary sample (acetaminophen,&#xD;
      GSH, biochemistry assay)&#xD;
&#xD;
      - Lunch before departure&#xD;
&#xD;
      2 weeks of wash-out&#xD;
&#xD;
      Period 2 : To Day 17 to Day 21&#xD;
&#xD;
      Same of period 1. Subject who receives N-acétylcystéine in period 1 will receive placebo in&#xD;
      second period and vice versa.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain intensity using Visual Analog Scales (VAS) succeeding thermic stimulations at the threshold temperature +3°C before (T0-1h) and after acetaminophen's administration</measure>
    <time_frame>At day 0</time_frame>
    <description>Pain intensity using Visual Analog Scales (VAS) succeeding thermic stimulations at the threshold temperature +3°C before (T0-1h) and after acetaminophen's administration (T0+1h, T0+2h, T0+3h, T0+4h).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood glutathione GSH concentration</measure>
    <time_frame>At day 0</time_frame>
    <description>Blood glutathione GSH concentration at J0 T0-1h and J0 T0+4h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood of acetaminophen concentration and its metabolites</measure>
    <time_frame>at day 0</time_frame>
    <description>Blood of acetaminophen concentration and its metabolites at J0 T0-1h, T0+2h, and T0+4h.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary assay of the rate of acetaminophen and its metabolites</measure>
    <time_frame>at day 0</time_frame>
    <description>Urinary assay of the rate of acetaminophen and its metabolites at J0 T0-1h, and T0+4h.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacogenetic dosage of enzymes involved in glutathione metabolism</measure>
    <time_frame>at day 4</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>acetaminophen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The purpose of this study is to assess the effectiveness of acetaminophen in association with N-acetylcysteine.&#xD;
The objective of this study is to evaluate if the association in healthy volunteers of acetaminophen and N-acétylcystéine&#xD;
- decrease the antinociceptive effect of acetaminophen in comparison to a group control&#xD;
- and if this antinociceptive effect may depend of the genetic polymorphism of GSH enzyme</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>- decrease the antinociceptive effect of acetaminophen in comparison to a group control&#xD;
- and if this antinociceptive effect may depend of the genetic polymorphism of GSH enzyme</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetylcysteine combination with acetaminophen</intervention_name>
    <arm_group_label>acetaminophen</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male&#xD;
&#xD;
          -  Between 18 and 45 years old&#xD;
&#xD;
          -  Without treatment during the 7 days before inclusion specially no use of antalgic and&#xD;
             anti-inflammatory&#xD;
&#xD;
          -  Cooperation and understanding enough to conform to the study obligations -Having given&#xD;
             free, informed written consent&#xD;
&#xD;
          -  Affiliated at system of French social security&#xD;
&#xD;
          -  Inscription or acceptation of inscription in the national register of volunteers&#xD;
             involved in trials.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with one or many contraindication for the administration of the trial's&#xD;
             products,&#xD;
&#xD;
          -  Patient that have taken N-acetylcysteine as bronchial thinner during the last 3 days,&#xD;
&#xD;
          -  Patient with medical or surgical history judged by the investigator or his&#xD;
             representative as being not compatible with the clinical trial&#xD;
&#xD;
          -  Patient with disease progression during inclusion,&#xD;
&#xD;
          -  Patient with excessive consumption of alcohol, tobacco (+ than 10 cigarette/day),&#xD;
             coffee, tea or drinks with caffeine (equivalent to more than 4 cup a day) or any&#xD;
             addiction to drugs,&#xD;
&#xD;
          -  Patient with a heat pain mean threshold during training higher or equal to 46.5°C,&#xD;
&#xD;
          -  Patient who participated in another clinical trial, located in exclusion period or&#xD;
             received benefits &gt; 4500 euros during 12 months before the beginning of trial,&#xD;
&#xD;
          -  Patient with cooperation and understanding that do not allow him to follow the trial,&#xD;
&#xD;
          -  Patients with minor or under guardianship,&#xD;
&#xD;
          -  No affiliation at system of French social security&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gisèle PICKERING</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>July 29, 2014</study_first_submitted>
  <study_first_submitted_qc>July 31, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2014</study_first_posted>
  <last_update_submitted>July 28, 2016</last_update_submitted>
  <last_update_submitted_qc>July 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

